上海阿拉丁生化科技股份有限公司 证券代码：688179 证券简称：阿拉丁 公告编号：2025-035 转债代码：118006 转债简称：阿拉转债 4、激励人数：首次授予人数 128 名，预留授予人数 29 名。 2021 年限制性股票激励计划首次授予部分 第三个归属期符合归属条件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次股权激励计划批准及实施情况 （一）本次股权激励计划主要内容 1、股权激励方式：第二类限制性股票。 2、授予数量：本激励计划首次授予数量 97.60 万股，预留授予数量 25.00 万股。 3、授予价格：40 元/股，即满足归属条件后，激励对象可以每股 40 元的价 格购买公司向激励对象增发的公司 A 股普通股股票。 | 第四个归属期 | | 40% | | --- | --- | --- | | 归属安排 | 归属时间 自授予之日起 52 个月后的首个交易日至授予之 日起 64 个月内的最后一个交易日止 | 归属权益数量占授予权 益总量的比例 | （2）公司层面业绩考核 ...

本次拟归属的激励对象符合《公司法》《证券法》等法律、法规和规范性文 件以及《公司章程》规定的任职资格，符合《管理办法》《上市规则》等法律、 法规和规范性文件规定的激励对象条件，符合本激励计划规定的激励对象范围， 其作为公司本激励计划激励对象的主体资格合法、有效，激励对象获授限制性股 票的归属条件已成就。 上海阿拉丁生化科技股份有限公司 监事会关于公司 2021 年限制性股票激励计划首次授予部分 第三个归属期归属名单的核查意见 上海阿拉丁生化科技股份有限公司（以下简称"公司"）监事会根据《中华 人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下 简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"）、 《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）等相关法律、 法规及规范性文件和《上海阿拉丁生化科技股份有限公司章程》（以下简称"《公 司章程》"）的有关规定，对公司 2021 年限制性股票激励计划（以下简称"本激 励计划"）首次授予部分第三个归属期符合归属条件的激励对象名单进行审核， 发表核查意见如下： 上海阿拉丁生化科技股份有限公司监事会 20 ...

| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2025-032 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于提请股东大会授权董事会决定以简易程序向特定 对象发行股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本次授权事项概述 根据《上市公司证券发行注册管理办法》、《上海证券交易所科创板上市公司证 券发行上市审核规则》、《上海证券交易所上市公司证券发行与承销业务实施细则》 等相关规定，公司于 2025 年 4 月 23 日召开的第四届董事会第三十七次会议，审议 通过《关于提请股东大会授权董事会办理以简易程序向特定对象发行股票相关事宜 的议案》，同意公司董事会提请股东大会授权董事会决定公司向特定对象发行融资 总额不超过人民币 3 亿元且不超过最近一年末净资产 20%的股票，授权期限自公司 2024 年年度股东大会审议通过之日起至公司 2025 年年度股东大会召开之日止。上 述议案尚需提交公司年度股东 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 130,180,313.51, representing a year-on-year increase of 32.20% compared to CNY 98,473,575.99 in the same period last year[4] - Net profit attributable to shareholders for the same period was CNY 24,182,495.49, up 41.35% from CNY 17,107,659.32 year-on-year[4] - Basic earnings per share rose by 50.00% to CNY 0.09 from CNY 0.06 in the previous year[5] - The company reported a diluted earnings per share of CNY 0.09, consistent with the basic earnings per share, indicating a 50.00% increase year-on-year[5] - Operating profit for Q1 2025 was ¥34,048,976.46, an increase of 74.5% from ¥19,518,862.64 in Q1 2024[19] - The company reported a total comprehensive income of ¥24,281,491.76 for Q1 2025, compared to ¥17,129,834.75 in Q1 2024[20] Cash Flow - The net cash flow from operating activities increased significantly by 130.14%, reaching CNY 33,690,148.03 compared to CNY 14,638,706.12 in the previous year[4] - Cash flow from operating activities for Q1 2025 was ¥33,690,148.03, compared to ¥14,638,706.12 in Q1 2024, indicating a significant improvement[21] - Cash flow from investing activities for Q1 2025 showed a net outflow of ¥41,285,281.53, worsening from a net outflow of ¥22,909,560.12 in Q1 2024[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,812,575,716.34, reflecting a 1.92% increase from CNY 1,778,424,528.59 at the end of the previous year[5] - The company's cash and cash equivalents decreased to RMB 421,402,808.68 from RMB 466,796,211.45, reflecting a decline of approximately 9.7%[15] - The total liabilities increased to RMB 659,013,937.99 from RMB 635,252,622.94, representing an increase of about 3.5%[17] - The company's equity attributable to shareholders rose slightly to RMB 1,071,043,938.29 from RMB 1,066,069,573.61, indicating a growth of approximately 0.5%[17] Research and Development - Research and development expenses totaled CNY 17,718,759.55, which is 13.61% of operating revenue, a slight decrease from 14.31% in the previous year[5] - The company experienced a significant increase in research and development expenses, which rose to ¥17,718,759.55 in Q1 2025 from ¥14,095,847.62 in Q1 2024[19] Shareholder Information - The total number of common shareholders at the end of the reporting period was 10,149[9] Investments - The company plans to invest RMB 4,117 million in Shanghai Yamei Biopharmaceutical Technology Co., acquiring a 25% stake[12][13] Inventory and Payables - The company's inventory increased to RMB 536,726,674.45 from RMB 528,264,759.16, showing a growth of about 1.7%[15] - The company's accounts payable rose to RMB 60,214,626.29 from RMB 43,991,332.27, marking an increase of approximately 37%[16] - The company's long-term investments increased to RMB 2,517,744.99 from RMB 2,450,253.26, reflecting a growth of about 2.8%[16] Borrowings - The company reported a decrease in short-term borrowings to RMB 31,487,321.64 from RMB 31,435,162.10, indicating a slight reduction[16]

Dividend and Share Capital - The company plans to distribute a cash dividend of 1.00 RMB per 10 shares, totaling approximately 27.61 million RMB (including tax) based on the remaining total share capital of 276,083,281 shares[6]. - The company intends to increase its share capital by 2 shares for every 10 shares held, resulting in a total increase of 55,216,656 shares, raising the total share capital to 331,299,937 shares[6]. - The company has not distributed any bonus shares in the current year[7]. - The cash dividend for the upcoming year is proposed at 1.00 CNY per 10 shares, with no capital increase or stock distribution planned[174]. - The total cash dividend amount for the last accounting year was 27,608,328.10 CNY, representing 27.95% of the net profit attributable to ordinary shareholders[179]. - The cumulative cash dividend over the last three accounting years amounts to 149,983,278.20 CNY, with an average net profit of 92,454,404.03 CNY, resulting in a cash dividend ratio of 162.22%[181]. Financial Performance - The company's operating revenue for 2024 reached CNY 533.56 million, representing a 32.44% increase compared to CNY 402.88 million in 2023[22]. - Net profit attributable to shareholders for 2024 was CNY 98.76 million, a 15.07% increase from CNY 85.83 million in 2023[22]. - The net cash flow from operating activities increased by 171.59% to CNY 151.52 million, up from CNY 55.79 million in the previous year[22]. - Total assets at the end of 2024 amounted to CNY 1,778.42 million, an 18.12% increase from CNY 1,505.55 million at the end of 2023[23]. - Basic earnings per share for 2024 were CNY 0.36, reflecting a 2.86% increase from CNY 0.35 in 2023[24]. - The company reported that the merger with Yuan Ye Bio contributed CNY 107 million in revenue and CNY 34.60 million in net profit during the second to fourth quarters of 2024[25]. - The company achieved a business revenue of ¥533,555,511.04, representing a year-on-year increase of 32.44%[36]. - The net profit attributable to shareholders reached ¥98,761,868.70, showing a year-on-year growth of 15.07%[36]. Research and Development - Research and development expenses accounted for 11.78% of operating revenue in 2024, down from 12.72% in 2023[24]. - The company invested approximately ¥62.86 million in R&D this year, marking a 22.66% increase from the previous year, although the proportion of R&D investment to operating income decreased by 0.94 percentage points to 11.78%[58]. - In 2024, the company applied for 16 new patents, including 1 domestic invention patent and 6 utility model patents[36]. - The company has developed over 3,200 analytical methods, enhancing its product performance characterization capabilities[70]. - The R&D team includes 4 PhD holders, 87 Master's degree holders, and 113 Bachelor's degree holders, indicating a strong educational background[67]. Market Position and Strategy - The company operates in four major fields: high-end chemistry, life sciences, analytical chromatography, and materials science, with a focus on research reagent production[37]. - The company is committed to the development of domestic research reagents, addressing the gap in the market compared to international competitors[44]. - The company has achieved a significant increase in domestic reagent varieties and quality, establishing a competitive stance against foreign brands due to lower prices and faster service response[47]. - The competitive landscape for high-end research reagents in China is dominated by international giants like Sigma-Aldrich and Thermo Fisher Scientific, while domestic companies are gradually gaining market share[120]. - The company aims to expand its product line in four key areas: high-end chemistry, life sciences, analytical chromatography, and materials science, focusing on R&D capability enhancement and product structure optimization[135]. Risks and Challenges - The company faces risks related to research and development failures, which could slow the introduction of new reagent products and impact sales growth[77]. - The company is at risk of losing core technology due to reliance on key personnel, which could adversely affect its competitive advantage[80]. - The company operates in a highly competitive market dominated by foreign enterprises, resulting in a low market share and increased competition[82]. - The company may experience a decline in profit margins due to increased competition and rising costs of raw materials and labor[87]. - The company faces risks related to inventory depreciation and slow turnover, which could negatively impact cash flow and financial stability[88][89]. Corporate Governance and Management - The company has a governance structure that includes a board of directors with specialized committees for audit, nomination, compensation, and strategy[195]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 4.2794 million RMB[155]. - The total remuneration for core technical personnel at the end of the reporting period amounted to 1.7116 million RMB[155]. - The company has no penalties from securities regulatory agencies in the past three years[156]. - The company is actively revising its stock incentive plan, with multiple proposals submitted for shareholder approval[166]. Environmental Responsibility - The company has established an environmental management system and emergency response mechanism for environmental incidents[193]. - The company reported a chemical oxygen demand (COD) concentration of 23 mg/L, well below the standard limit of 500 mg/L for wastewater discharge[199]. - Total nitrogen concentration was measured at 23 mg/L, which is within the acceptable limit of 70 mg/L[199]. - Total phosphorus concentration was recorded at 3.94 mg/L, significantly lower than the standard limit of 8 mg/L[199]. - The company generated 12.51 tons of waste pharmaceuticals, with a total of 15.789 tons stored at the end of the year[200].

关于上海阿拉丁生化科技股份有限公司 募集资金年度存放与实际使用情况 的鉴证报告 众环专字（2025）2300421号 关于募集资金年度存放与实际使用情况的专项报告 1 目 录 起始页码 鉴证报告 1 募集资金专项报告 -上海阿拉丁生化科技股份有限公司 金年度存放与实际使用情况的鉴证报告 众环专字（2025）2300421 号 上海阿拉丁生化科技股份有限公司全体股东: 我们接受委托,对后附的上海阿拉丁生化科技股份有限公司(以下简称"阿拉丁公司") 截至 2024 年 12 月 31 日止的《2024 年度募集资金年度存放与实际使用情况的专项报告》进 行了鉴证工作。 按照中国证监会发布的《上市公司监管指引第 2 号 -- 上市公司募集资金管理和使用的 监管要求》和上海证券交易所发布的《上海证券交易所科创板上市公司自律监管指引第 1 号 -- 规范运作》等有关规定,编制《2024年度募集资金年度存放与实际使用情况的专项 报告》,提供真实、合法、完整的实物证据、原始书面材料、副本材料、口头证言以及我们 认为必要的其他证据,是阿拉丁公司董事会的责任。我们的责任是在执行鉴证工作的基础上, 对《2024年度募集资金年度存放 ...

关于上海阿拉丁生化科技股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 委托单位： 目 录 1、 专项审计报告 2、 附表 审计单位： 联系电话： 关于上海阿拉丁生化科技股份有限公司 非经营性资金占用及其他关联资金往来情况汇总表 的专项审核报告 众环专字(2025) 2300420 号 上海阿拉丁生化科技股份有限公司全体股东: 我们接受委托,在审计了上海阿拉丁生化科技股份有限公司(以下简称"阿拉丁")2024 年 12月 31 日合并及公司的资产负债表,2024年度合并及公司的利润表、合并及公司的现 金流量表和合并及公司的股东权益变动表以及财务报表附注的基础上,对后附的《上市公司 2024 年度非经营性资金占用及其他关联资金往来的情况汇总表》(以下简称"汇总表")进 行了专项审核。按照中国证券监督管理委员会印发的《上市公司监管指引第 8 号 -- 上市公 司资金往来、对外担保的监管要求》的规定,编制和披露汇总表、提供真实、合法、完整的 审核证据是阿拉丁管理层的责任,我们的责任是在执行审核工作的基础上对汇总表发表专项 审核意见。 我们按照中国注册会计师审计准则的相关规定执行了审核工作。 ...

西部证券股份有限公司 关于上海阿拉丁生化科技股份有限公司 2025 年度日常关联交易预计 的核查意见 保荐人（主承销商） （陕西省西安市新城区东新街 319 号 8 幢 10000 室） 西部证券股份有限公司 关于上海阿拉丁生化科技股份有限公司 2025 年度日常关联交易预计的核查意见 西部证券股份有限公司（以下简称"西部证券"或"保荐人"）为上海阿拉 丁生化科技股份有限公司（以下简称"阿拉丁"或"公司"）持续督导阶段的保 荐人。根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上 市规则》及《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等有关规定，对阿拉丁 2025 年度日常关联交易预计的事项进行了审慎核查，核 查情况及核查意见如下： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 1、独立董事专门会议审议情况 就本次日常关联交易预计事项，公司独立董事在董事会审议前召开了专门会 议，并一致审议通过了《关于 2025 年度日常关联交易预计的议案》。公司独立 董事认为：公司 2025 年度预计发生的日常关联交易事项为公司开展日常生产经 营所需，相关交易遵循协商一致、 ...

关于上海阿拉丁生化科技股份有限公司 2024 年度募集资金存放与使用情况的核查意见 保荐人（主承销商） （陕西省西安市新城区东新街 319 号 8 幢 10000 室） 西部证券股份有限公司 西部证券股份有限公司 关于上海阿拉丁生化科技股份有限公司 2024 年度募集资金存放与使用情况的核查意见 西部证券股份有限公司（以下简称"西部证券"或"保荐人"）作为上海阿 拉丁生化科技股份有限公司（以下简称"阿拉丁"或"公司"）持续督导阶段的 保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作》及《上海证券交易所科创板股票上市规 则》等有关规定，对阿拉丁 2024 年度募集资金的存放和使用情况进行了专项核 查，核查情况如下： 一、募集资金基本情况 （一）实际募集资金到账情况 1、首次公开发行股票 经上海证券交易所科创板上市委员会 2020 年 8 月 11 日审核同意，并经中国 证券监督管理委员会 2020 年 9 月 7 日《关于同意上海阿拉丁生化科技股份有限 公司首次公开发行股票注册的批复》（证监许可【2020】2116 号）注册同意， 公司向社会公开发行 ...

上海市锦天城律师事务所 关于上海阿拉丁生化科技股份有限公司 2021 年限制性股票激励计划 调整、首次授予部分第三个归属期归属条件成就及 部分已授予尚未归属限制性股票作废相关事项的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9、11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海阿拉丁生化科技股份有限公司 2021 年限制性股票激励计划 调整、首次授予部分第三个归属期归属条件成就及 部分已授予尚未归属限制性股票作废相关事项的 法律意见书 01F20245294 致：上海阿拉丁生化科技股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受上海阿拉丁生化科技股份有限公司 （以下简称"公司"或"阿拉丁"）的委托，并根据公司与本所签订的法律服务合同，作为公 司 2021 年限制性股票激励计划（以下简称"本次激励计划"）的法律顾问。 本所根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（ ...